Replimune is set to resubmit its advanced melanoma treatment, RP1, for FDA approval after receiving a new opportunity due to a shakeup in FDA leadership. Following productive discussions with the agency, Replimune hopes that this third attempt will be successful. The stock experienced significant gains, surging over 80% as investors reacted positively to the news of FDA prioritization of the review. Despite previous rejections, Replimune remains optimistic that aligned objectives with the FDA will chart a successful path forward for its cancer immunotherapy.